Argos Therapeutics (ARGS) & Mediwound (MDWD) Critical Comparison
Argos Therapeutics (NASDAQ: ARGS) and Mediwound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.
Earnings and Valuation
This table compares Argos Therapeutics and Mediwound’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Argos Therapeutics||$950,000.00||15.17||-$53.02 million||($1.12)||-0.15|
|Mediwound||$1.56 million||82.88||-$18.88 million||($0.64)||-7.47|
Mediwound has higher revenue and earnings than Argos Therapeutics. Mediwound is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
18.4% of Argos Therapeutics shares are held by institutional investors. Comparatively, 29.5% of Mediwound shares are held by institutional investors. 28.2% of Argos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Argos Therapeutics and Mediwound, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Argos Therapeutics currently has a consensus price target of $1.20, suggesting a potential upside of 631.71%. Mediwound has a consensus price target of $9.80, suggesting a potential upside of 105.02%. Given Argos Therapeutics’ higher probable upside, research analysts clearly believe Argos Therapeutics is more favorable than Mediwound.
This table compares Argos Therapeutics and Mediwound’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Argos Therapeutics has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Mediwound has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500.
Mediwound beats Argos Therapeutics on 9 of the 14 factors compared between the two stocks.
About Argos Therapeutics
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.